drugset / Trial / NCT01426802

Vildagliptin 50 mg Twice Daily in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin

NCT01426802

Phase 4 Completed 150 enrolled Novartis Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

The study is designed to demonstrate the short term efficacy and safety of vildagliptin 50 mg bid in patients with Type 2 Diabetes Mellitus inadequately controlled with Metformin.

Timeline

Start
2010-10
Primary completion
2011-04
Completion
2011-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Vildagliptin Other / unclassified 50 mg